Olmesartan Medoxomilo Tolife (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks the AT1 receptor for angiotensin II, preventing the hormone from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels, decreased peripheral resistance, and a reduction in blood pressure.

The appropriate dose of Olmesartan Medoxomilo Tolife is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any relevant comorbidities. Patients should follow the prescriber’s instructions exactly.

Olmesartan medoxomil is generally contraindicated during pregnancy because it can affect fetal development. Women who are pregnant, planning to become pregnant, or are breastfeeding should discuss alternative antihypertensive options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Olmesartan belongs to the ARB class, which blocks the AT1 receptor, whereas ACE inhibitors block the conversion of angiotensin I to II. Both lower blood pressure, but ARBs like olmesartan are less likely to cause cough or angioedema, making them a preferred option for patients intolerant to ACE inhibitors.

Olmesartan Medoxomilo Tolife should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight.

Olmesartan Medoxomilo Tolife is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their clinician.

Serious risks include hyperkalemia, acute kidney injury, severe hypotension, and rare cases of angioedema. Patients should be monitored for signs of swelling, rapid drop in blood pressure, or worsening kidney function, especially when used with other medications that affect potassium or renal function.

Olmesartan Medoxomilo Tolife should be avoided in patients with known hypersensitivity to olmesartan or any component of the formulation, those with severe renal impairment, and pregnant women. Individuals with a history of angioedema or uncontrolled hyperkalemia should also discuss alternatives with their doctor.